Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

globenewswire

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile – NEWSnet – News… as it used to be

More Press Releases

May 1, 2026

Bronstein, Gewirtz & Grossman LLC Urges New Era Energy & Digital, Inc. (f/k/a New Era Helium Inc.) Investors to Act: Class Action Filed Alleging Investor Harm

May 1, 2026

TEMO Inc. brings back its Limited Lifetime Transferable Warranty

May 1, 2026

Dr. Maureen Spranza selected as Top Elementary School Music Teacher by IAOTP

May 1, 2026

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

Bronstein, Gewirtz & Grossman LLC Urges New Era Energy & Digital, Inc. (f/k/a New Era Helium Inc.) Investors to Act: Class Action Filed Alleging Investor Harm

TEMO Inc. brings back its Limited Lifetime Transferable Warranty

Dr. Maureen Spranza selected as Top Elementary School Music Teacher by IAOTP

Angela Cusack Selected as Empowered Woman of the Year by IAOTP